Nonalcoholic fatty liver disease (NAFLD) is a pressing public health concern. NAFLD is recognized as a disease with systemic involvement. Erectile dysfunction is a prevalent condition among men.The study examined the relationship between nonalcoholic fatty liver disease, assessed via US Fatty Liver Index (USFLI), and erectile dysfunction.This study used cross-sectional data from individuals over 20 years old who took part in the National Health and Nutrition Examination Survey between 2001 and 2004, collecting details on their ED, USFLI, and several other essential variables. A USFLI score equal to or exceeding 30 was chosen to diagnose NAFLD, while a USFLI score below 10 was utilized to exclude the presence of fatty liver.There were 3 763 participants, with 29.1% (1,095/3,763) who experienced ED. After Accounting for all potential covariates, USFLI was positively associated with erectile dysfunction (OR, 1.02; 95% CI, 1.02 ~ 1.03; P < 0.001). Compared with individuals with Q1 (USFLI < 10), the adjusted OR values for USFLI and ED in Q2 (10 ≤ USFLI < 30) and Q3 (USFLI ≥ 30, NAFLD) were 1.84 (95% CI: 1.46 ~ 2.32, p < 0.001) and 2.18 (95% CI: 1.66 ~ 2.87, p < 0.001), respectively. The association USFLI and ED exhibited an L-shaped curve (nonlinear, P = 0.014). The OR of developing erectile dysfunction was 1.03 (95% CI: 1.021 ~ 1.04, P < 0.001) in participants with USFLI < 50.18. This study identi ed a positive correlation between USFLI and ED within the adult American population. Our ndings imply that NAFLD might constitute an independent risk factor for ED.
IntroducionErectile dysfunction (ED) is de ned as the consistent or recurrent inability to attain and/or maintain penile erection su cient for successful vaginal intercourse(1). ED is the most prevalent condition among men in their middle and older years(2).It is projected that by 2025, over 322 million men worldwide will have experienced ED, with up to 30 million affected in the United States alone(3).The evolving trends present a formidable challenge for public health systems in formulating policies aimed at preventing or mitigating ED.Nonalcoholic fatty liver disease (NAFLD) is a pressing public health concern, given its escalating prevalence. In a recent systematic review and meta-analysis, it was revealed that NAFLD's prevalence on a global scale is approaching nearly onethird(4). Approximately 24% of the U.S. population is estimated to be affected by NAFLD(5). NAFLD is recognized as a disease with systemic involvement. NAFLD not only leads to liver brosis, cirrhosis, and hepatocellular carcinoma but also poses a signi cant risk factor for the development of cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD)(6, 7). Some studies have highlighted a potential connection between NAFLD and ED(8, 9). The U.S. fatty liver index (USFLI) is a validated, non-invasive approach for evaluating NAFLD and has been employed in prior research studies (10).Therefore, we aimed to further explore the relationship between NAFLD, ass...